Principal Financial Group Inc Chinook Therapeutics, Inc. Transaction History

Principal Financial Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$18.66 - $38.58 $6,624 - $13,695	355 Added 1.46%	24,599 $945,000
Q1 2023 May 09, 2023	SELL	$21.53 - $26.8 $6,695 - $8,334	-311 Reduced 1.27%	24,244 $561,000
Q4 2022 Feb 09, 2023	BUY	$18.63 - $27.35 $231,030 - $339,167	12,401 Added 102.03%	24,555 $643,000
Q3 2022 Nov 09, 2022	SELL	$17.51 - $23.37 $163,858 - $218,696	-9,358 Reduced 43.5%	12,154 $239,000
Q2 2022 Aug 10, 2022	BUY	$12.59 - $18.8 $270,836 - $404,425	21,512 New	21,512 $376,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.